
To evaluate the effect of canagliflozin, a sodium‐glucose co‐transporter‐2 (SGLT2) inhibitor, on albuminuria and the decline of estimated glomerular filtration rate (eGFR) in participants with type 2 diabetes and microalbuminuria. The rate of eGFR declines before intervention is estimated, followed by a 52‐week intervention and a 4‐week washout period. The CANPIONE study will determine whether the SGLT2 inhibitor canagliflozin can reduce albuminuria and slow eGFR decline in type 2 diabetes and microalbuminuria participants.
Like
Save
Share